Syndax Pharmaceuticals
SNDX
57 hedge funds and large institutions have $79.8M invested in Syndax Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 3 closing their positions.
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
27% more funds holding
Funds holding: 45 → 57 (+12)
2.6% less ownership
Funds ownership: 63.75% → 61.15% (-2.6%)
37% less capital inflows, than outflows
Capital inflows: $9.36M | Capital outflows: $14.9M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EverPoint Asset Management
Stamford,
Connecticut
|
+$2.19M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.9M |
| 3 |
Millennium Management
New York
|
+$1.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.07M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$616K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.73M |
| 2 |
Jennison Associates
New York
|
-$3.18M |
| 3 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.21M |
| 4 |
EcoR1 Capital
San Francisco,
California
|
-$915K |
| 5 |
General Electric
Evendale,
Ohio
|
-$726K |
SNDX Hedge Fund Activity: Q4 2016 in Review
57 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2016, worth a combined $79.8M — down 55% from $176M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new SNDX positions and 3 closed out — a net gain of 12 holders — while 15 added to existing stakes and 11 trimmed.
The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $2.19M. The largest seller was Fidelity Investments, cutting an estimated $6.73M.
- 57 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2016, up from 45 in Q3 2016.
- Funds reported $79.8M of Syndax Pharmaceuticals stock for Q4 2016, down 55% quarter-over-quarter.
- 15 funds opened new Syndax Pharmaceuticals positions in Q4 2016 and 3 closed out, a net change of +12 holders.
- The largest Syndax Pharmaceuticals buyer in Q4 2016 was EverPoint Asset Management, an estimated $2.19M added.
- The largest Syndax Pharmaceuticals seller in Q4 2016 was Fidelity Investments, an estimated $6.73M sold.
Based on aggregated 13F filings for Q4 2016.